CD4 and metastatic neoplasm: Immune subset analyses revealed that the combination therapy not only enhanced CD4+Foxp3- T-cell expansion at the metastatic tumor site (lung) and in the periphery (spleen and DLN), but also augmented memory formation compared to the untreated and monotherapy controls.